Related Experiment Video
Updated: Mar 21, 2026
High-Resolution Cardiac Positron Emission Tomography/Computed Tomography for Small Animals
Published on: December 16, 2022
Comparison of Iohexol-380 and Iohexol-350 for Coronary CT Angiography: A Multicenter, Randomized, Double-Blind Phase
Eun-Ah Park1, Whal Lee1, Doo Kyoung Kang2
1Department of Radiology, Seoul National University Hospital, Seoul 03080, Korea.
Insights
Iohexol-380 offers better enhancement in the ascending aorta during coronary CT angiography compared to iohexol-350. Both contrast agents demonstrated similar safety profiles and image quality in healthy subjects.
Area of Science:
- Radiology
- Medical Imaging
- Cardiovascular Imaging
Background:
- Coronary CT angiography (CCTA) is a vital diagnostic tool.
- Optimizing contrast agent performance is crucial for diagnostic accuracy.
- Iohexol is a widely used iodinated contrast medium.
Purpose of the Study:
- To compare the safety and efficacy of iohexol-380 versus iohexol-350 for CCTA.
- To evaluate contrast enhancement and image quality between the two agents.
- To assess adverse event profiles of iohexol-380 and iohexol-350.
Main Methods:
- Phase 3, multi-center, randomized, double-blind trial.
- 225 healthy subjects received either iohexol-380 or iohexol-350 at 4 mL/sec.
- Image quality and luminal attenuation (Hounsfield units) were assessed by blinded readers.
Main Results:
- No significant difference in adverse drug reactions or serum creatinine levels between groups.
- Iohexol-380 showed significantly higher mean density in the ascending aorta (p=0.030).
- No significant differences in image quality scores for coronary arteries were observed.
Conclusions:
- Iohexol-380 provides superior enhancement of the ascending aorta compared to iohexol-350.
- Both agents exhibit comparable safety and image quality for CCTA.
- Iohexol-380 is a safe and effective alternative for CCTA with improved aortic enhancement.
Objective:
This multi-center, randomized, double-blind, phase 3 trial was conducted to compare the safety and efficacy of contrast agents iohexol-380 and iohexol-350 for coronary CT angiography in healthy subjects.
Materials And Methods:
Volunteers were randomized to receive 420 mgI/kg of either iohexol-350 or iohexol-380 using a flow rate of 4 mL/sec. All adverse events were recorded. Two blinded readers independently reviewed the CT images and conflicting results were resolved by a third reader. Luminal attenuations (ascending aorta, left main coronary artery, and left ventricle) in Hounsfield units (HUs) and image quality on a 4-point scale were calculated.
Results:
A total of 225 subjects were given contrast media (115 with iohexol-380 and 110 with iohexol-350). There was no difference in number of adverse drug reactions between groups: 75 events in 56 (48.7%) of 115 subjects in the iohexol-380 group vs. 74 events in 51 (46.4%) of 110 subjects in the iohexol-350 group (p = 0.690). No severe adverse drug reactions were recorded. Neither group showed an increase in serum creatinine. Significant differences in mean density between the groups was found in the ascending aorta: 375.8 ± 71.4 HU with iohexol-380 vs. 356.3 ± 61.5 HU with iohexol-350 (p = 0.030). No significant differences in image quality scores between both groups were observed for all three anatomic evaluations (all, p > 0.05).
Conclusion:
Iohexol-380 provides improved enhancement of the ascending aorta and similar attenuation of the coronary arteries without any increase in adverse drug reactions, as compared with iohexol-350 using an identical amount of total iodine.
